Evidence map›Paper›PMID 27642637›Full record

ArticlemSphere

Zinc Pyrithione Improves the Antibacterial Activity of Silver Sulfadiazine Ointment.

Catlyn Blanchard, Lauren Brooks, Katherine Ebsworth-Mojica, Louis Didione, Benjamin Wucher, Stephen Dewhurst, Damian Krysan, Paul M Dunman, Rachel A F Wozniak

Open access · goldAbstract read
In one paragraph

Article in mSphere. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Efficacy of a Biocidal Paint in ControllingAnimals : an open access journal from MDPI · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Copper Coordination Compounds as Biologically Active Agents.International journal of molecular sciences · 2020
    Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Catlyn BlanchardDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Lauren BrooksDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Katherine Ebsworth-MojicaDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Louis DidioneDepartment of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Benjamin WucherDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Stephen DewhurstDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Damian KrysanDepartment of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Paul M DunmanDepartment of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Rachel A F WozniakDepartment of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
University of Rochester · US

Funding

Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Development of AK-based assays for antimicrobial screeningR01AI103507 · NIAID · UNIVERSITY OF ROCHESTER · PI DUNMAN, PAUL M. · 2013 to 2015
$1.1M
The Semen Enhancer of HIV Infection as a Novel Microbicide TargetR33AI094511 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2013 to 2015
$1.1M
The Semen Enhancer of HIV Infection as a Novel Microbicide TargetR21AI094511 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2011 to 2012
$434k
NIAID NIH HHS P30 AI078498NIAID NIH HHS R01 AI103507NIAID NIH HHS R21 AI094511NIAID NIH HHS R33 AI094511
6 · The paper itself

Abstract

Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus are commonly associated with biofilm-associated wound infections that are recalcitrant to conventional antibiotics. As an initial means to identify agents that may have a greater propensity to improve clearance of wound-associated bacterial pathogens, we screened a Food and Drug Administration-approved drug library for members that display bactericidal activity toward 72-h-established P. aeruginosa biofilms using an adenylate kinase reporter assay for bacterial cell death. A total of 34 compounds displayed antibiofilm activity. Among these, zinc pyrithione was also shown to reduce levels of A. baumannii and S. aureus biofilm-associated bacteria and exhibited an additive effect in combination with silver sulfadiazine, a leading topical therapeutic for wound site infections. The improved antimicrobial activity of zinc pyrithione and silver sulfadiazine was maintained in an ointment formulation and led to improved clearance of P. aeruginosa, A. baumannii, and S. aureus in a murine model of wound infection. Taken together, these results suggest that topical zinc pyrithione and silver sulfadiazine combination formulations may mitigate wound-associated bacterial infections and disease progression. IMPORTANCE Topical antimicrobial ointments ostensibly mitigate bacterial wound disease and reliance on systemic antibiotics. Yet studies have called into question the therapeutic benefits of several traditional topical antibacterials, accentuating the need for improved next-generation antimicrobial ointments. Yet the development of such agents consisting of a new chemical entity is a time-consuming and expensive proposition. Considering that drug combinations are a mainstay therapeutic strategy for the treatment of other therapeutic indications, one alternative approach is to improve the performance of conventional antimicrobial ointments by the addition of a well-characterized and FDA-approved agent. Here we report data that indicate that the antimicrobial properties of silver sulfadiazine ointments can be significantly improved by the addition of the antifungal zinc pyrithione, suggesting that such combinations may provide an improved therapeutic option for the topical treatment of wound infections.

Indexed as

Acinetobacter baumanniibiofilmPseudomonas aeruginosasilver sulfadiazineStaphylococcus aureuswoundzinc pyrithione

Identifiers

PMID27642637
PMCPMC5023846
OpenAlexW2519120686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.